Targets › C5
8 programs from 6 companies in 41 trials: 25 Phase 3, 7 Phase 4, 7 Phase 2, 2 Phase 1; Neurology, Hematology, Ophthalmology; next expected readout Dec 2026.
Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Activated downstream of classical, alternative, lectin and GZMK complement pathways..; FUNCTION: [Complement C5b]: Component of the membrane attack complex (MAC), a…. (UniProt, P01031)
Open in Phaseline: the race on C5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Ravulizumab Complement C5 inhibitor | C5 | Phase 4 | aHUS; Generalized Myasthenia Gravis; Delayed Graft Function; NMOSD … | Jun 2027 |
| Astellas | Avacincaptad Pegol Sodium (ASP3021) Complement C5 inhibitor | C5 | Phase 4 | Geographic Atrophy | Jun 2027 |
| Regeneron Pharmaceuticals | Pozelimab Complement C5 inhibitor | C5 | Phase 4 | CHAPLE Disease; Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis … | Jul 2028 |
| AstraZeneca | eculizumab Complement C5 inhibitor | C5 | Phase 3 | NMOSD; Neuromyelitis Optica Spectrum Disorder Attack; Neuromyelitis Optica Spectrum Disorders (NMOSD); Hypertensive Emergency-associated Hemolytic Uremic Syndrome … | Dec 2026 |
| Roche | Crovalimab Complement C5 inhibitor | C5 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome | Jan 2027 |
| Regeneron Pharmaceuticals | Cemdisiran Complement C5 mRNA RNAi inhibitor | C5 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis | Jul 2028 |
| UCB Biopharma SRL | Zilucoplan Complement C5 inhibitor | C5 | Phase 2 | Generalized Myasthenia Gravis; Healthy Participants; Generalized Myasthenia Gravis (gMG); Amyotrophic Lateral Sclerosis | Mar 2027 |
| PPD Development, LP | vilobelimab Complement C5 inhibitor | C5 | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
Paroxysmal Nocturnal Hemoglobinuria (9) Generalized Myasthenia Gravis (6) NMOSD (4) Age-related Macular Degeneration (AMD) (2) Atypical Hemolytic Uremic Syndrome (2) Acute Respiratory Distress Syndrome (ARDS) (2) Neuromyelitis Optica Spectrum Disorder Attack (2) aHUS (1) Delayed Graft Function (1) IgAN (1) Immunoglobulin A Nephropathy (1) Neuromyelitis Optica Spectrum Disorder (1)
antibody (5), small molecule (2), mixed (1)
AstraZeneca (2) Regeneron Pharmaceuticals (2) Roche (1) Astellas (1) UCB Biopharma SRL (1) PPD Development, LP (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.